Clinical trial
A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
NCT02795988 is registered in ClinicalTrials.gov with Imugene Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
- Lead sponsor
- Imugene Limited
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 30, 2017
- Completion date
- March 20, 2024
- Enrollment
- 64 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.